CURE Expects Higher Demand for Transdermal Drug Delivery Platform

Pharmaceutical Investing

CURE Pharmaceutical announced it is now expecting an increase in the demand for their transdermal drug delivery platform, which uses an epidermis penetration enhancer.

CURE Pharmaceutical (OTCQB:CURR) announced it is now expecting an increase in the demand for their transdermal drug delivery platform, which uses an epidermis penetration enhancer.
As quoted in the press release:

recent research report by Research and Markets predicts the Global Transdermal Drug Delivery Market to grow at a CAGR of around 11.6% over the next decade to reach approximately $95.57 billion by 2025.
CURE’s innovative transdermal drug delivery platform, formulated to deliver a therapeutically effective amount of drug across a patient’s skin, utilizes an epidermis penetration enhancer called a vasodilator that is used to open the pores sufficiently to enable the passive transport of active ingredients, combined with carrier solvents across the epidermis layer of the skin and into the dermis and subdermal tissue.
“Transdermal drug delivery is one of our proprietary drug delivery technologies that helps us support our mission to improve people’s lives by redefining how medicines and health products are delivered and experienced,” said CEO of CURE Rob Davidson. “We expect to experience increased demand for our transdermal products as consumers and the healthcare industry increasingly turn to drug delivery methods that result in improved drug delivery and medication compliance.”

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×